Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Bernstein Reaffirms Their Hold Rating on Bristol-Myers Squibb (BMY)

Tipranks - Tipranks - Wed Apr 1, 1:20PM CDT

In a report released yesterday, Courtney Breen from Bernstein maintained a Hold rating on Bristol-Myers Squibb, with a price target of $58.00.

End of Quarter Sale - 50% Off TipRanks

According to TipRanks, Breen is a 4-star analyst with an average return of 19.4% and an 84.09% success rate. Breen covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Moderna, and Merck & Company.

Currently, the analyst consensus on Bristol-Myers Squibb is a Moderate Buy with an average price target of $62.67.

See the top stocks recommended by analysts >>

Based on Bristol-Myers Squibb’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $12.5 billion and a net profit of $1.09 billion. In comparison, last year the company earned a revenue of $12.34 billion and had a net profit of $72 million

Read More on BMY:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).